Fundraising FoxArsenal Bridge Venture — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Courage Therapeutics is a neuroendocrine biotech developing MC4R agonist drugs for genetic obesity; its lead candidate CTX-B is a weekly injectable targeting melanocortin-4 receptor haploinsufficiency (MC4R HI), a form of early-onset severe obesity with no approved targeted therapy.
BiotechHealthtechLongevityNewton, US
Roger Cone(Co-Founder & CSO)Dan Housman(Co-Founder)Giovanni Ferrara(CEO)Tomi Sawyer(Chief Medicinal Chemist)Sasha Blaug(CBO-CFO)George Grass(Head of Non-Clinical)
Board seatIsaac Barchas· per SEC Form D · $10.5M raise · filed May 2025
Co-investorsAugment Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.